αvβ8

αVβ8-IN-1 is an inhibitor of the αVβ8 integrin. It exhibits growth-suppressive activity against tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 is suitable for research related to idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and various cancers.

MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).

SF0166 is a potent, selective antagonist of α v β 3, demonstrating IC 50 values of 0.6 nM for α v β 3, 8 nM for α v β 6, and 13 nM for α v β 8. It effectively inhibits cellular adhesion to vitronectin in human, rat, rabbit, and dog cell lines, with IC 50 values ranging from 7.6 pM to 76 nM. Additionally, SF0166 significantly reduces neovascularization in the oxygen-induced retinopathy mouse model.

CWHM-12 is a potent inhibitor of αV integrins, with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively.

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, targets specific cell lines, and elicits particular cell responses by binding to integrins. It is the most effective and frequently used peptide sequence for stimulated cell adhesion on synthetic surfaces. Among the 24 integrins that bind to ECM molecules in an RGD-dependent manner are α3β1, α5β1, α8β1, αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and to some extent α2β1 and α4β1.

Integrin-IN-2 is an orally bioavailable pan αv integrin inhibitor.Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively.